|BioWeek一周事-MedSci.cn - 风湿免疫
Baidu
map

超级医保局挂牌,CAR-T治疗有望被颠覆…|BioWeek一周事

2018-06-03 佚名 生物探索

本周,国家医疗保障局(以下简称“国家医保局”)正式挂牌。至此,国务院新组建部门和单位已全部亮相。妇幼司公开340家产前诊断技术的医疗机构最新名单。宾夕法尼亚大学的 Carl H. June带领团队发表了一项重磅成果:一名接受CAR-T疗法治疗的慢性淋巴细胞白血病患者已5年无癌……更多资讯,请跟随小编一起回顾吧。

1

产业动态

医保局正式挂牌!从“三保合一”到“定价招标”,新时代开启



5月31日,医药圈被“国家医保局挂牌”的新闻刷屏。在《深化党和国家机构改革方案》大刀阔斧整合精简的大背景下,国务院直属机构中与医疗相关的机构——国家医疗保障局正式上岗!挂牌当日,首届领导班子集体亮相:胡静林任局长,施子海、陈金甫、李滔任副局长。

GEN:基因编辑之下,罕见病治疗触目可及



尽管基因治疗发展迅速,但从技术角度看,目前针对单基因疾病的基因疗法似乎更可行。据统计,在已被确认的7000种罕见疾病中,单基因疾病约占80 %。因此,在大多数临床试验从严重的联合免疫缺陷病等单基因疾病转向心脏病和癌症等多基因疾病之前,罕见病可能是基因疗法的首要应用领域。

30项!近6亿!2018年“干细胞及转化研究”重点专项拟立项项目公示



5月29日,科技部中国生物技术发展中心网站公示:国家重点研发计划“干细胞及转化研究”重点专项2018年度拟立项项目信息,拟立项项目共计30项,共计获得中央财政经费5.8544亿元,单个项目获得中央财政经费最多近3000万元。

专访 | 李明辉博士:用“表观星图”寻找每个人的专属“星座”



2017 年 12 月 28 日,“中国十万人基因组计划”启动。次年,“表观星图计划(Epigenetics Atlas Project)”也宣布启动,这是国内首个大型甲基化组项目,旨在通过与国内外基因组队列计划联动,建立中国人甲基化基准数据库,为表观遗传领域研究、应用和临床检测等建立基础数据库。近日,生物探索有幸采访了表观星图计划首席科学家、中科普瑞技术产品总监李明辉博士,请他分享了创建中国人甲基化数据库的故事。

340家!妇幼司公开:产前诊断技术的医疗机构最新名单



产前筛查诊断)是预防新生儿缺陷的关键防线。近日,为加强产前诊断技术管理,方便群众接受产前诊断技术服务,国家卫生健康委员会汇总了全国经批准开展产前诊断技术的医疗机构名单:截至2017年12月31日,全国经批准可开展产前诊断技术服务的医疗机构共有340家。

专访 | 久心医疗CEO孙建燕:首款国产自主研发AED获批上市,赢得心脏除颤“黄金时间”



毕业36年的孙建燕前24年从事过声呐研究、“做过”空调和电脑,后12年,他却彻底成为了一名“医疗器械人”。自2006年以来,孙建燕历经了3家公司:加入微创医疗,他促使公司心脏支架成本降低了2/3;在诺尔康,他推动国内首款人工耳蜗成功拿到注册证并上市销售;如今,在他创办的久心医疗,经过不到6年的时间,公司自主研发的首款国产半自动体外除颤器已获批上市,打破了长达十多年的进口垄断。

2

研究动态

Nature重磅:惊人成果!只用1个CAR-T细胞,让患者5年“无癌”



宾夕法尼亚大学的 Carl H. June教授是CAR-T领域公认的“大牛”。在最新一期的Nature中,他带领团队发表了一项重磅成果:一名接受CAR-T疗法治疗的慢性淋巴细胞白血病患者已5年无癌(cancer free)。更重要的是,研究发现,CAR-T疗法发挥抗癌作用所需的最小剂量仅为1个细胞!

又1篇Science!施一公组发表冷冻电镜新成果



2018年5月25日,清华大学生命科学学院、结构生物学高精尖创新中心施一公教授研究组就剪接体的组装机理与结构研究于《科学》(Science)杂志以长文形式再次发表重大研究成果。

再亮“绿灯”!日本科学家计划:利用iPSCs治疗心脏病



5月29日,在《Nature》期刊发表的一篇题为“‘Reprogrammed’ stem cells approved to mend human hearts for the first time”的新闻中,日本科学家们第一次获卫生部批准,将使用诱导性多能干细胞(iPSCs)治疗心脏病。这是iPSCs继黄斑变性之后的第二个临床应用。

驳斥先前观点!Nature里程碑:除基因突变,“太干净”也会导致儿童癌症



科学家们就儿童白血病的起源已经争论了一个多世纪。5月21日,发表在Nature Reviews Cancer上的一篇重要综述首次揭示了大多数儿童白血病的可能原因。让人惊讶的是,分析结果显示,细菌和病毒感染在其中发挥了极其关键的作用。这一重要发现也被BBC以《缺失微生物“导致”儿童癌症》(Missing microbes 'cause' childhood cancer)为题进行了报道。

AI大战皮肤科医生首份成果:人类又输了…



5月28日,在ANNALS OF ONCOLOGY上发表的一项研究中,来自德、美、法三国的研究人员开发了一个深度学习卷积神经网络(CNN),并通过展示10万多幅恶性黑色素瘤和良性痣的图像来让它识别皮肤癌。而且,在CNN与58位国际皮肤科医生的“PK赛”中, CNN比皮肤科医生更少漏诊黑素瘤,误诊良性黑素瘤的几率更低。

证实了!学习物理真的能让脑袋变灵活



来自美国德雷塞尔大学一项新的研究证明,人们在面临解决物理问题时,传统上与学习科学无关的大脑部分会变得活跃起来。这一发现表明了大脑的活动可以通过不同的教学形式来改变。

又是肠道菌!Science揭示:靶向细菌或可治疗肝癌



肠道微生物是近几年医药研究领域的热点,被誉为人类的"第二基因组",同时也是人体内的一个“隐形”器官。近期,一篇发表在《Science》期刊上的文章揭示:肠道菌与肝脏的抗肿瘤免疫反应存在关联,前者是后者的重要调控因子。

新疗法?科学家证明脑刺激可改善糖尿病症状|Science子刊



大脑正在成为系统葡萄糖代谢的重要调节者。从动物和观察性人类研究中积累的数据表明,纹状体多巴胺信号在葡萄糖调节中起作用,但一直缺乏直接证据。近日,来自荷兰和美国耶鲁大学的一份证据表明,脑深部刺激(DBS)可以帮助治疗2型糖尿病

45岁不能再晚啦!新研究建议:这一癌症应提前筛查



美国癌症协会(ACS)和其他预防指南组织对结直肠癌风险人群进行筛查的年龄建议是50岁。然而最新数据显示,50岁以下人群的结直肠癌发病率不断上升,在某些情况下,他们的发病率更高。因此可能需要尽早开始筛查。这项研究建议,筛查年龄最好从45岁就开始。

3

特别策划

青春不散场,最美毕业照征集



童靴们,毕业照、实验照、秀恩爱照、自黑照、仙女照、小哥哥照……欢迎疯狂砸向探索君!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918113, encodeId=3070191811359, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 27 13:18:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781237, encodeId=5a6a1e81237be, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Nov 09 23:18:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351065, encodeId=82c1351065e8, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 31 16:46:16 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280394, encodeId=dea71280394d3, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jun 05 02:18:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321187, encodeId=ff7f32118e7b, content=期待好转了., beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 03 17:17:21 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321173, encodeId=95593211e3cb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jun 03 16:00:05 CST 2018, time=2018-06-03, status=1, ipAttribution=)]
    2019-01-27 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918113, encodeId=3070191811359, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 27 13:18:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781237, encodeId=5a6a1e81237be, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Nov 09 23:18:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351065, encodeId=82c1351065e8, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 31 16:46:16 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280394, encodeId=dea71280394d3, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jun 05 02:18:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321187, encodeId=ff7f32118e7b, content=期待好转了., beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 03 17:17:21 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321173, encodeId=95593211e3cb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jun 03 16:00:05 CST 2018, time=2018-06-03, status=1, ipAttribution=)]
    2018-11-09 仁心济世
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918113, encodeId=3070191811359, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 27 13:18:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781237, encodeId=5a6a1e81237be, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Nov 09 23:18:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351065, encodeId=82c1351065e8, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 31 16:46:16 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280394, encodeId=dea71280394d3, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jun 05 02:18:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321187, encodeId=ff7f32118e7b, content=期待好转了., beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 03 17:17:21 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321173, encodeId=95593211e3cb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jun 03 16:00:05 CST 2018, time=2018-06-03, status=1, ipAttribution=)]
    2018-10-31 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1918113, encodeId=3070191811359, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 27 13:18:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781237, encodeId=5a6a1e81237be, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Nov 09 23:18:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351065, encodeId=82c1351065e8, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 31 16:46:16 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280394, encodeId=dea71280394d3, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jun 05 02:18:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321187, encodeId=ff7f32118e7b, content=期待好转了., beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 03 17:17:21 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321173, encodeId=95593211e3cb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jun 03 16:00:05 CST 2018, time=2018-06-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1918113, encodeId=3070191811359, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 27 13:18:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781237, encodeId=5a6a1e81237be, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Nov 09 23:18:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351065, encodeId=82c1351065e8, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 31 16:46:16 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280394, encodeId=dea71280394d3, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jun 05 02:18:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321187, encodeId=ff7f32118e7b, content=期待好转了., beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 03 17:17:21 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321173, encodeId=95593211e3cb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jun 03 16:00:05 CST 2018, time=2018-06-03, status=1, ipAttribution=)]
    2018-06-03 1e0f8808m18(暂无匿称)

    期待好转了.

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1918113, encodeId=3070191811359, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 27 13:18:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781237, encodeId=5a6a1e81237be, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Nov 09 23:18:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351065, encodeId=82c1351065e8, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 31 16:46:16 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280394, encodeId=dea71280394d3, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Jun 05 02:18:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321187, encodeId=ff7f32118e7b, content=期待好转了., beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 03 17:17:21 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321173, encodeId=95593211e3cb, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jun 03 16:00:05 CST 2018, time=2018-06-03, status=1, ipAttribution=)]
    2018-06-03 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

相关资讯

Nat Med:大牛Carl June“现身”新论文,预测CAR-T疗效,它非常可靠!

宾夕法尼亚大学的 Carl H. June教授是CAR-T领域公认的“大牛”。近日,他参与发表的一篇最新论文找到了一种能够预测慢性淋巴细胞白血病患者将如何响应CAR-T疗法的T细胞生物标志物。在小部分患者中的初步验证研究显示,该标志物的预测准确率高达100%。

Nature:这个意外突变,有望颠覆 CAR- T 治疗!

今日,顶尖学术期刊《自然》在线刊登了一项重磅研究。癌症免疫疗法大牛、CAR- T 疗法先驱 Carl June 教授共同领导的一支科研团队,意外发现了一个可能颠覆传统 CAR- T 治疗的基因突变。它有望让原本治疗无望的白血病患者得到临床治愈。

CAR-T细胞疗法和基因治疗能实现可持续销售吗?

自2012年诺华加入到宾夕法尼亚大学个性化CAR-T癌症治疗项目以来,分析师们一直在思考一个棘手的问题:基因治疗公司该如何从患者身上获利呢?

Nat Med:同日两篇研究发现CAR-T毒性控制新理论,抑制IL-1可降低巨噬细胞产生CRS的风险

现如今,CAR-T在血液肿瘤乃至某些实体瘤上的成功和不俗表现大家都早已耳熟能详,随着两款CAR-T细胞药物的获批上市,这一领域已然热到滚烫,迅速成为了生物医药领域的重点突破方向,但关于CAR-T疗法的毒性作用也一直如鲠在喉。

CAR-T迎来利好 中国药企或可与全球巨头同台竞技

近日,美国医疗保险和医疗补助服务中心(CMS)宣布将CAR-T疗法囊括进医保报销的范围之内,这令许多人开始关注CAR-T技术。近年来,该技术从临床前研究到临床应用一直都在快速发展着。业内人士称,在肿瘤治疗领域,它正在成为下一个具有爆发力的市场。未来十年的市场空间将达百亿美元2017年是CAR-T疗法的元年,FDA批准了两款CAR-T疗法上市。第一款是来自诺华的Kymriah,于2017年8月获批。

Nat Med:CAR-T疗法带来“新惊喜”!有效清除脑肿瘤

4月16日,一项CAR-T疗法突破进展发表在Nature Medicine杂志上。来自斯坦福大学医学院的科学家们首次证实,靶向GD2的CAR-T细胞能够在小鼠模型中战胜一种致命的儿童脑肿瘤——脑干胶质瘤DIPG。

Baidu
map
Baidu
map
Baidu
map